{"title":"The clinical practice guideline for the management of amyotrophic lateral sclerosis in Japan-update 2023.","authors":"Makoto Urushitani, Hitoshi Warita, Naoki Atsuta, Yuishin Izumi, Osamu Kano, Toshio Shimizu, Yuki Nakayama, Yugo Narita, Hiroyuki Nodera, Takuji Fujita, Koichi Mizoguchi, Mitsuya Morita, Masashi Aoki","doi":"10.5692/clinicalneurol.cn-001946","DOIUrl":null,"url":null,"abstract":"<p><p>Amyotrophic lateral sclerosis (ALS) is an adult-onset intractable motor neuron disease characterized by selective degeneration of cortical neurons in the frontotemporal lobe and motor neurons in the brainstem and spinal cord. Impairment of these neural networks causes progressive muscle atrophy and weakness that spreads throughout the body, resulting in life-threatening bulbar palsy and respiratory muscle paralysis. However, no therapeutic strategy has yet been established to halt ALS progression. Although evidence for clinical practice in ALS remains insufficient, novel research findings have steadily accumulated in recent years. To provide updated evidence-based or expert consensus recommendations for the diagnosis and management of ALS, the ALS Clinical Practice Guideline Development Committee, approved by the Japanese Society of Neurology, revised and published the Japanese clinical practice guidelines for the management of ALS in 2023. In this guideline, disease-modifying therapies that have accumulated evidence from randomized controlled trials were defined as \"Clinical Questions,\" in which the level of evidence was determined by systematic reviews. In contrast, \"Questions and Answers\" were defined as issues of clinically important but insufficient evidence, according to reports of a small number of cases, observational studies, and expert opinions. Based on a literature search performed in February 2022, recommendations were reached by consensus, determined by an independent panel, reviewed by external reviewers, and submitted for public comments by Japanese Society of Neurology members before publication. In this article, we summarize the revised Japanese guidelines for ALS, highlighting the regional and cultural diversity of care processes and decision-making. The guidelines cover a broad range of essential topics such as etiology, diagnostic criteria, disease monitoring and treatments, management of symptoms, respiration, rehabilitation, nutrition, metabolism, patient instructions, and various types of care support. We believe that this summary will help improve the daily clinical practice for individuals living with ALS and their caregivers.</p>","PeriodicalId":39292,"journal":{"name":"Clinical Neurology","volume":" ","pages":"252-271"},"PeriodicalIF":0.0000,"publicationDate":"2024-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Neurology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5692/clinicalneurol.cn-001946","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/23 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Amyotrophic lateral sclerosis (ALS) is an adult-onset intractable motor neuron disease characterized by selective degeneration of cortical neurons in the frontotemporal lobe and motor neurons in the brainstem and spinal cord. Impairment of these neural networks causes progressive muscle atrophy and weakness that spreads throughout the body, resulting in life-threatening bulbar palsy and respiratory muscle paralysis. However, no therapeutic strategy has yet been established to halt ALS progression. Although evidence for clinical practice in ALS remains insufficient, novel research findings have steadily accumulated in recent years. To provide updated evidence-based or expert consensus recommendations for the diagnosis and management of ALS, the ALS Clinical Practice Guideline Development Committee, approved by the Japanese Society of Neurology, revised and published the Japanese clinical practice guidelines for the management of ALS in 2023. In this guideline, disease-modifying therapies that have accumulated evidence from randomized controlled trials were defined as "Clinical Questions," in which the level of evidence was determined by systematic reviews. In contrast, "Questions and Answers" were defined as issues of clinically important but insufficient evidence, according to reports of a small number of cases, observational studies, and expert opinions. Based on a literature search performed in February 2022, recommendations were reached by consensus, determined by an independent panel, reviewed by external reviewers, and submitted for public comments by Japanese Society of Neurology members before publication. In this article, we summarize the revised Japanese guidelines for ALS, highlighting the regional and cultural diversity of care processes and decision-making. The guidelines cover a broad range of essential topics such as etiology, diagnostic criteria, disease monitoring and treatments, management of symptoms, respiration, rehabilitation, nutrition, metabolism, patient instructions, and various types of care support. We believe that this summary will help improve the daily clinical practice for individuals living with ALS and their caregivers.
肌萎缩性脊髓侧索硬化症(ALS)是一种成人发病的顽固性运动神经元疾病,其特征是额颞叶皮质神经元以及脑干和脊髓的运动神经元发生选择性变性。这些神经网络的损伤会导致进行性肌肉萎缩和无力,并扩散到全身,导致危及生命的球麻痹和呼吸肌麻痹。然而,目前还没有阻止 ALS 进展的治疗策略。虽然 ALS 的临床实践证据仍然不足,但近年来新的研究成果不断积累。为了给 ALS 的诊断和治疗提供最新的循证医学证据或专家共识建议,经日本神经病学学会批准,ALS 临床实践指南制定委员会于 2023 年修订并发布了日本 ALS 临床实践指南。在该指南中,已从随机对照试验中积累证据的疾病改变疗法被定义为 "临床问题",其证据水平由系统综述决定。而 "问题与答案 "则是根据少数病例报告、观察性研究和专家意见,定义为具有临床重要性但证据不足的问题。根据 2022 年 2 月进行的文献检索,我们在达成共识的基础上提出了建议,这些建议由一个独立小组确定,由外部评审员进行审查,并在发表前提交给日本神经病学学会成员征求公众意见。在本文中,我们总结了修订后的日本 ALS 指南,强调了护理流程和决策的地区和文化多样性。该指南涵盖了病因学、诊断标准、疾病监测和治疗、症状管理、呼吸、康复、营养、代谢、患者指导以及各类护理支持等广泛的基本主题。我们相信,这份摘要将有助于改善 ALS 患者及其护理人员的日常临床实践。